Friday, March 23, 2012
MATTER by Matter — Kickstarter
MATTER by Matter — Kickstarter
# THE PROBLEM
The web is the future of journalism, but let's be honest: the future isn’t living up to expectations. Newspapers and magazines have cut back on in-depth reporting. Gossip sites have proliferated. The web has become a byword for fast and cheap. Why isn’t it synonymous with fearless, investigative and enthralling writing?.........
Does the world really need more science journalism? Matter says yes, and thousands agree - GenOmics
Blogger's Note: 'Matter' is a proposed new journal with iphone-like costs - .99 cents
Does the world really need more science journalism? Matter says yes, and thousands agree - GenOmics
Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release)
Myriad Genetics Announces the Release of Support360.com - DigitalJournal.com (press release):
Myriad Genetics Announces the Release of Support360.com
DigitalJournal.com (press release) The site is a unique, personalized resource for information and encouragement about risk testing for hereditary forms of breast, ovarian and other types of cancers, including Hereditary Breast and Ovarian Cancer Syndrome and Lynch Syndrome. and more » |
Endocyte Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates - financial news (EC145/Vintafolide/Etarfolatide)
Endocyte Receives USAN Approval for Nonproprietary Names of Novel Endocyte Drug Candidates (Nasdaq:ECYT)
"March 22, 2012 (GLOBE NEWSWIRE) --
Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the World Health Organization and the United States Adopted Names (USAN) Council have approved the nonproprietary name "vintafolide" (pronounced vin ta foe' lide) for Endocyte's therapeutic drug candidate EC145 and the nonproprietary name of "etarfolatide" (pronounced et" ar foe' la tide) for Endocyte's companion imaging agent EC20. Vintafolide and etarfolatide are currently being evaluated in the Phase 3 PROCEED trial for the treatment of women with folate-receptor positive platinum-resistant ovarian cancer. Etarfolatide is being used to select patients with tumors that over-express folate receptors and who are most likely to benefit from vintafolide therapy. Endocyte intends to file European Marketing Authorisation Applications for both agents based on positive Phase 2 results............."
Pathol. 2012 - abstract (Japan) "Piling up" clear cells in müllerian-type mucinous and mixed cell-type borderline tumor do not represent concomitant clear cell neoplasms (mucinous/mixed/clear cell/borderline/ER....)
Hum Pathol. 2012 Mar 19. [Epub ahead of print]
"Piling up" clear cells in müllerian-type mucinous and mixed cell-type borderline tumor do not represent concomitant clear cell neoplasms.
Abstract
The nature of "piling up" proliferation of clear cells in müllerian mucinous/mixed borderline tumor has not been well characterized. The purpose of this study was to clarify whether or not such clear cells represent concomitant clear cell neoplasms.First, we carefully reviewed hematoxylin and eosin slides taken from 139 ovarian tumors diagnosed as clear cell carcinoma (112 cases) and müllerian mucinous/mixed borderline tumor (27 cases) to clarify (1) the frequency of piling-up clear cells in müllerian mucinous/mixed borderline tumor and (2) the frequency of the coexistence of typical clear cell carcinoma and müllerian mucinous/mixed borderline tumor.
Second, we investigated the immunohistochemical expression of estrogen receptor, hepatocyte nuclear factor-1β, and glypican-3 in proliferating clear cells in both tumors.
We identified piling-up clear cells in 56% of müllerian mucinous/mixed borderline tumors. Such clear cells lacked the severe nuclear atypia, complex branching, and dense hyalinized cores of typical clear cell carcinoma. We did not find coexistence of typical clear cell carcinoma and müllerian mucinous/mixed borderline tumor in any tumors.
Piling-up clear cells and endocervical-like mucinous cells were positive for estrogen receptor but negative for hepatocyte nuclear factor-1β and glypican-3. Most clear cell carcinomas showed a hepatocyte nuclear factor-1β-positive/estrogen receptor-negative immunophenotype, and about half of them were glypican-3 positive.
In conclusion, piling-up clear cells in müllerian mucinous/mixed borderline tumor do not represent concomitant clear cell neoplasms because clear cell carcinoma and müllerian mucinous/mixed borderline tumor hardly ever coexist and because such clear cells in both tumors are immunophenotypically distinct.
http://www.asianoncologysummit.com/
Subscribe to:
Posts
(
Atom
)
Posts
